当前位置： SCI文献检索 > LEUKEMIA期刊下所有文献 > Mitoxantrone and ara-C in previously treated patients with acute myelogenous leukemia.

Mitoxantrone and ara-C in previously treated patients with acute myelogenous leukemia.

Abstract：

:Mitoxantrone is a synthetic aminoanthraquinone we have previously reported to be effective for patients with acute leukemia in relapse. We presently report the results of a trial of mitoxantrone in combination with cytosine arabinoside (ara-C) in patients with refractory or relapsed acute myelocytic leukemia (AML). Forty-nine patients, 24 males and 25 females, with a median age of 56, of whom 32 were in first relapse, four were in second relapse, and 13 had primarily refractory AML, were treated with mitoxantrone 10 mg/m2 daily for 3 days and ara-C 100 mg/m2 daily by continuous infusion for 7 days. Twenty patients (62.5%) with first relapse AML achieved M1 marrow, whereas only two of 13 patients with refractory AML did; none of four patients with more than one prior remission responded. Marrow recovery was observed in a median of 32 days. Remissions were maintained with monthly ara-C plus mitoxantrone alternating with ara-C plus 6-TG; median duration of remission was 8 months and two patients are in continuing remission at 8 and 16 months. Treatment was well tolerated, with minimal nausea and vomiting, diarrhea, drug-induced mucositis. Treatment-related cardiac toxicity was not observed. Transient hepatic dysfunction was observed in greater than 50% of courses. Mitoxantrone plus ara-C is an active combination with great promise for the therapy of previously untreated patients with AML.

journal_name

Leukemia

journal_title

Leukemia

authors

Paciucci PA,Dutcher JP,Cuttner J,Strauman JJ,Wiernik PH,Holland JF

subject

Has Abstract

pub_date

1987-07-01 00:00:00

pages

565-7

issue

7

eissn

0887-6924

issn

1476-5551

journal_volume

1

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • The percentage of myeloperoxidase-positive blast cells is a strong independent prognostic factor in acute myeloid leukemia, even in the patients with normal karyotype.

    abstract：:To examine whether the percentage of myeloperoxidase (MPO)-positive blast cells is useful as a prognostic factor for acute myeloid leukemia (AML), cytochemical analysis of MPO was performed in 491 patients who were registered to the Japan Adult Leukemia Study Group-AML92 study. Patients were divided into two using the...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2403010

    authors： Matsuo T,Kuriyama K,Miyazaki Y,Yoshida S,Tomonaga M,Emi N,Kobayashi T,Miyawaki S,Matsushima T,Shinagawa K,Honda S,Ohno R,Japan Adult Leukemia Study Group.

    更新日期：2003-08-01 00:00:00

  • Epstein-Barr virus in T and natural killer (NK) cell non-Hodgkin's lymphomas.

    abstract：:Several studies using sensitive in situ hybridization techniques show that, in non-immunocompromised patients, Epstein-Barr virus (EBV) is more frequently detected in lymphomas expressing T cell markers than in B cell lymphomas. Among lymphomas expressing T cell markers, the presence of EBV is highly related to the si...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：

    authors： Kanavaros P,Briere J,Emile JF,Gaulard P

    更新日期：1996-06-01 00:00:00

  • Insights in dynamic kinome reprogramming as a consequence of MEK inhibition in MLL-rearranged AML.

    abstract：:Single kinase-targeted cancer therapies often failed prolonged responses because cancer cells bypass through alternative routes. In this study, high-throughput kinomic and proteomic approaches enabled to identify aberrant activity profiles in mixed lineage leukemia (MLL)-rearranged acute myeloid leukemia (AML) that de...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2013.342

    authors： Kampen KR,Ter Elst A,Mahmud H,Scherpen FJ,Diks SH,Peppelenbosch MP,de Haas V,Guryev V,de Bont ES

    更新日期：2014-03-01 00:00:00

  • Expression of the CEA gene family members NCA-50/90 and NCA-160 (CD66) in childhood acute lymphoblastic leukemias (ALLs) and in cell lines of B-cell origin.

    abstract：:The carcinoembryonic antigen (CEA) and the classical non-specific cross-reacting antigens (NCAs) belong to the CEA gene family which is part of the immunoglobulin superfamily. In normal hematopoiesis, CEA gene family members (CGMs) have only been reported on cells of myeloid and monocytic origin. In the present study,...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Hanenberg H,Baumann M,Quentin I,Nagel G,Grosse-Wilde H,von Kleist S,Göbel U,Burdach S,Grunert F

    更新日期：1994-12-01 00:00:00

  • Genetic studies of childhood acute lymphoblastic leukemia with emphasis on p16, MLL, and ETV6 gene abnormalities: results of St Jude Total Therapy Study XII.

    abstract：:To determine the frequency and prognostic significance of recently described genetic lesions in pediatric acute lymphoblastic leukemia (ALL), all cases with available leukemic cell samples treated on St Jude Study XII were analyzed by molecular techniques for alterations of the p16, MLL and ETV6 genes. Homozygous p16 ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2400779

    authors： Rubnitz JE,Behm FG,Pui CH,Evans WE,Relling MV,Raimondi SC,Harrison PL,Sandlund JT,Ribeiro RC,Grosveld G,Downing JR

    更新日期：1997-08-01 00:00:00

  • Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia?

    abstract：:Two proteins that have been correlated with the occurrence of multidrug resistance in acute myeloid leukemia (AML) are P-glycoprotein (Pgp) and the major vault protein (Mvp/LRP). With the purpose of further quantifying the potential contributions of Pgp-mediated drug efflux and Mvp/LRP to drug resistance in AML we hav...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401331

    authors： Broxterman HJ,Sonneveld P,Pieters R,Lankelma J,Eekman CA,Loonen AH,Schoester M,Ossenkoppele GJ,Löwenberg B,Pinedo HM,Schuurhuis GJ

    更新日期：1999-02-01 00:00:00

  • Expression of p16INK4A and p14ARF in hematological malignancies.

    abstract：:The INK4A/ARF locus yields two tumor suppressors, p16INK4A and p14ARF, and is frequently deleted in human tumors. We studied their mRNA expressions in 41 hematopoietic cell lines and in 137 patients with hematological malignancies; we used a quantitative reverse transcription-PCR assay. Normal peripheral bloods, bone ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401557

    authors： Taniguchi T,Chikatsu N,Takahashi S,Fujita A,Uchimaru K,Asano S,Fujita T,Motokura T

    更新日期：1999-11-01 00:00:00

  • The TLR1/2 agonist PAM(3)CSK(4) instructs commitment of human hematopoietic stem cells to a myeloid cell fate.

    abstract：:Toll-like receptors (TLRs) constitute a family of nonpolymorphic receptors that are devoted to pathogen recognition. In this work, we have explored the impact of TLR ligands (TLR-L) on human hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs). We show that HSCs and HPCs have a comparable pattern ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2009.155

    authors： De Luca K,Frances-Duvert V,Asensio MJ,Ihsani R,Debien E,Taillardet M,Verhoeyen E,Bella C,Lantheaume S,Genestier L,Defrance T

    更新日期：2009-11-01 00:00:00

  • A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia.

    abstract：:Chronic myelomonocytic leukemia (CMML) is a complex clonal hematological disorder classified among myelodysplastic (MDS)/myeloproliferative neoplasms. Prognosis is poor and there is a lack of effective treatments. The hypomethylating agent decitabine has shown activity against MDS and elderly acute myeloid leukemia, b...

    journal_title：Leukemia

    pub_type： 杂志文章,多中心研究

    doi：10.1038/leu.2017.186

    authors： Santini V,Allione B,Zini G,Gioia D,Lunghi M,Poloni A,Cilloni D,Sanna A,Masiera E,Ceccarelli M,Abdel-Wahab O,Terenzi A,Angelucci E,Finelli C,Onida F,Pelizzari A,Ferrero D,Saglio G,Figueroa M,Levis A

    更新日期：2018-02-01 00:00:00

  • Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol.

    abstract：:Alterations in the FLT3 gene, including internal tandem duplications (ITDs) and D835 mutations occur frequently in acute myelogenous leukemia. We investigated the prevalence and clinico-biological correlations of FLT3 ITDs and D835 mutations in 90 patients with acute promyelocytic leukemia (APL) receiving the AIDA pro...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402723

    authors： Noguera NI,Breccia M,Divona M,Diverio D,Costa V,De Santis S,Avvisati G,Pinazzi MB,Petti MC,Mandelli F,Lo Coco F

    更新日期：2002-11-01 00:00:00

  • Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning.

    abstract：:Relapse of malignant disease remains the major complication in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after hematopoietic cell transplantation (HCT) with reduced-intensity conditioning (RIC). In this study, we investigated the predictive value of disease-specific markers (DSMs), d...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2010.283

    authors： Lange T,Hubmann M,Burkhardt R,Franke GN,Cross M,Scholz M,Leiblein S,Al-Ali HK,Edelmann J,Thiery J,Niederwieser D

    更新日期：2011-03-01 00:00:00

  • TET1 promotes growth of T-cell acute lymphoblastic leukemia and can be antagonized via PARP inhibition.

    abstract：:T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological cancer characterized by skewed epigenetic patterns, raising the possibility of therapeutically targeting epigenetic factors in this disease. Here we report that among different cancer types, epigenetic factor TET1 is highly expressed in T-ALL a...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-020-0864-3

    authors： Bamezai S,Demir D,Pulikkottil AJ,Ciccarone F,Fischbein E,Sinha A,Borga C,Te Kronnie G,Meyer LH,Mohr F,Götze M,Caiafa P,Debatin KM,Döhner K,Döhner H,González-Menéndez I,Quintanilla-Fend L,Herold T,Jeremias I,Feuring-

    更新日期：2020-05-15 00:00:00

  • Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study.

    abstract：:Early molecular response is associated with improved probability of deep molecular response and superior survival in patients with CML-CP. However, ~1 in 3 patients on first-line imatinib do not achieve this threshold. The phase 2b DASCERN trial (NCT01593254) assessed the outcome of early switch to dasatinib in patien...

    journal_title：Leukemia

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1038/s41375-020-0805-1

    authors： Cortes JE,Jiang Q,Wang J,Weng J,Zhu H,Liu X,Hochhaus A,Kim DW,Radich J,Savona M,Martin-Regueira P,Sy O,Gurnani R,Saglio G

    更新日期：2020-08-01 00:00:00

  • Role of catalase in monocytic differentiation of U937 cells by TPA: hydrogen peroxide as a second messenger.

    abstract：:Human promonocytic cell line U937 cells can be induced to differentiate into macrophages by treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA). TPA treatment induced the expression of the monocytic differentiation markers CD11b and CD36, with concomitant morphological changes. Moreover, TPA enhanced reactive ox...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2008.353

    authors： Yamamoto T,Sakaguchi N,Hachiya M,Nakayama F,Yamakawa M,Akashi M

    更新日期：2009-04-01 00:00:00

  • High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia.

    abstract：:We explored the relationship between time to relapse and different exposure variables (serum methotrexate (S-MTX) 23, 36 and 42 h after start of administration, MTX elimination time and leucovorin (LV) dose) during high-dose MTX (HDM) treatment of 445 children with acute lymphoblastic leukemia. MTX was infused at 5 g/...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2404404

    authors： Skärby TV,Anderson H,Heldrup J,Kanerva JA,Seidel H,Schmiegelow K,Nordic Society of Paediatric Haematology and Oncology (NOPHO).

    更新日期：2006-11-01 00:00:00

  • Suppression of c-myc and c-myb expression in myeloid cell lines treated with recombinant tumor necrosis factor-alpha.

    abstract：:Proto-oncogenes are thought to be involved in cellular differentiation and proliferation. Tumor necrosis factors (TNFs) are specific cytokines that have cytostatic and cytotoxic effects in vitro against a wide range of human tumor cells. We have previously demonstrated that recombinant TNFs (rTNFs) have an antiprolife...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Schachner J,Blick M,Freireich E,Gutterman J,Beran M

    更新日期：1988-11-01 00:00:00

  • Comparison of outcome in acute myelogenous leukemia patients with translocation (8;21) found by standard cytogenetic analysis and patients with AML1/ETO fusion transcript found only by PCR testing.

    abstract：:Patients with normal-karyotype acute myelogenous leukemia (NKAML) may have undetected genetic abnormalities that could affect prognosis. Screening for known AML-specific genetic abnormalities using the reverse transcription polymerase chain reaction (RT-PCR) may help in arriving at a more definitive prognosis. To test...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401951

    authors： Sarriera JE,Albitar M,Estrov Z,Gidel C,Aboul-Nasr R,Manshouri T,Kornblau S,Chang KS,Kantarjian H,Estey E

    更新日期：2001-01-01 00:00:00

  • Childhood monosomy 7 syndrome: clinical and in vitro studies.

    abstract：:The clinical and cell growth characteristics of 11 children with monosomy 7 presenting as preleukemia (eight cases) or acute nonlymphoblastic leukemia (three cases) were studied. Anemia was common to all patients, with nine showing leukocytosis, seven thrombocytopenia, and one thrombocytosis. There was a striking pred...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Weiss K,Stass S,Williams D,Kalwinsky D,Dahl GV,Wang W,Johnson FL,Murphy SB,Dow LW

    更新日期：1987-02-01 00:00:00

  • SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine "storm" and risk factor for damage of hematopoietic stem cells.

    abstract：:The scientific community faces an unexpected and urgent challenge related to the SARS-CoV-2 pandemic and is investigating the role of receptors involved in entry of this virus into cells as well as pathomechanisms leading to a cytokine "storm," which in many cases ends in severe acute respiratory syndrome, fulminant m...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/s41375-020-0887-9

    authors： Ratajczak MZ,Kucia M

    更新日期：2020-07-01 00:00:00

  • Proteomic analysis of childhood leukemia.

    abstract：:Childhood acute lymphoblastic and myeloid leukemias are stratified into molecular and cytogenetic subgroups important for prognosis and therapy. Studies have shown that gene expression profiles can discriminate between leukemia subtypes. Thus, proteome analysis similarly holds the potential for characterizing differen...

    journal_title：Leukemia

    pub_type： 杂志文章,多中心研究

    doi：10.1038/sj.leu.2403897

    authors： Hegedus CM,Gunn L,Skibola CF,Zhang L,Shiao R,Fu S,Dalmasso EA,Metayer C,Dahl GV,Buffler PA,Smith MT

    更新日期：2005-10-01 00:00:00

  • ProMACE-cytaBOM versus MACOP-B in intermediate and high grade NHL. Preliminary results of a prospective randomized trial.

    abstract：:One hundred seventy-nine patients with intermediate or high-grade non-Hodgkin's lymphoma were randomized to receive either ProMACE-CytaBOM (P-C) or MACOP-B (M-B). At last follow-up 71 patients in the P-C arm and 78 in the M-B arm were assessable for response. Forty-one patients treated with P-C (58%) and 49 patients t...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：

    authors： Federico M,Moretti G,Gobbi PG,Avanzini P,Cavanna L,Carotenuto M,Lombardo M,Leone G,Pitini V,Abbadessa V

    更新日期：1991-01-01 00:00:00

  • Induction of microRNAs, mir-155, mir-222, mir-424 and mir-503, promotes monocytic differentiation through combinatorial regulation.

    abstract：:Acute myeloid leukemia (AML) involves a block in terminal differentiation of the myeloid lineage and uncontrolled proliferation of a progenitor state. Using phorbol myristate acetate (PMA), it is possible to overcome this block in THP-1 cells (an M5-AML containing the MLL-MLLT3 fusion), resulting in differentiation to...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2009.246

    authors： Forrest AR,Kanamori-Katayama M,Tomaru Y,Lassmann T,Ninomiya N,Takahashi Y,de Hoon MJ,Kubosaki A,Kaiho A,Suzuki M,Yasuda J,Kawai J,Hayashizaki Y,Hume DA,Suzuki H

    更新日期：2010-02-01 00:00:00

  • Pharmacokinetics of idarubicin after oral administration in elderly leukemic patients.

    abstract：:We have studied the plasma pharmacokinetics of idarubicin (4-demethoxy daunorubicin) in 11 elderly patients suffering from acute myeloblastic leukemia receiving orally 30 mg/m2 per day for 3 consecutive days. Idarubicin culminated in plasma 4 hr after administration and followed three similar time courses after the th...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章,多中心研究

    doi：

    authors： Robert J,Rigal-Huguet F,Huet S,Pris J,Hurteloup P

    更新日期：1990-03-01 00:00:00

  • Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia.

    abstract：:Adults with acute lymphoblastic leukemia (ALL) do worse than children. From 7/2008 to 12/2014, Nordic and Baltic centers treated 1509 consecutive patients aged 1-45 years with Philadelphia chromosome-negative ALL according to the NOPHO ALL2008 without cranial irradiation. Overall, 1022 patients were of age 1-9 years (...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2017.265

    authors： Toft N,Birgens H,Abrahamsson J,Griškevičius L,Hallböök H,Heyman M,Klausen TW,Jónsson ÓG,Palk K,Pruunsild K,Quist-Paulsen P,Vaitkeviciene G,Vettenranta K,Åsberg A,Frandsen TL,Marquart HV,Madsen HO,Norén-Nyström U,Schmi

    更新日期：2018-03-01 00:00:00

  • Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy.

    abstract：:To determine the clinical significance of minimal residual disease (MRD) in patients with prognostically relevant subtypes of childhood acute lymphoblastic leukemia (ALL), we analyzed data from 488 patients treated in St Jude Total Therapy Study XV with treatment intensity based mainly on MRD levels measured during re...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2016.234

    authors： Pui CH,Pei D,Raimondi SC,Coustan-Smith E,Jeha S,Cheng C,Bowman WP,Sandlund JT,Ribeiro RC,Rubnitz JE,Inaba H,Gruber TA,Leung WH,Yang JJ,Downing JR,Evans WE,Relling MV,Campana D

    更新日期：2017-02-01 00:00:00

  • Internal tandem duplication of the flt3 gene found in acute myeloid leukemia.

    abstract：:We analyzed mRNA expression of the flt3 gene in 30 patients with acute myeloid leukemia (AML) and 50 with acute lymphoblastic leukemia (ALL). Using reverse transcriptase-polymerase chain reaction (RT-PCR), expression of flt3 was observed in 61 patients; 22 (73%) with AML and 39 (78%) with ALL. Among these, five patien...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Nakao M,Yokota S,Iwai T,Kaneko H,Horiike S,Kashima K,Sonoda Y,Fujimoto T,Misawa S

    更新日期：1996-12-01 00:00:00

  • Idarubicin DNA intercalation is reduced by MRP1 and not Pgp.

    abstract：:Currently available data regarding the substrate specificity of the multi-drug resistance (MDR) mechanisms P-glycoprotein (Pgp) and MDR-associated protein (MRP1) for idarubicin are inconclusive. A multiparameter flow cytometry method was developed which allows simultaneous quantitative measurement of total cellular fl...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401496

    authors： Smeets ME,Raymakers RA,Vierwinden G,Pennings AH,Boezeman J,Minderman H,de Witte TM

    更新日期：1999-09-01 00:00:00

  • Intraclonal diversification of immunoglobulin light chains in a subset of chronic lymphocytic leukemia alludes to antigen-driven clonal evolution.

    abstract：:The study of intraclonal diversification (ID) in immunoglobulin (IG) genes offers valuable insight into the role of ongoing interactions with antigen in lymphomagenesis. We recently showed that ID in the IG heavy chain genes of patients with chronic lymphocytic leukemia (CLL) was generally limited; however, intense ID...

    journal_title：Leukemia

    pub_type： 杂志文章,多中心研究

    doi：10.1038/leu.2010.90

    authors： Kostareli E,Sutton LA,Hadzidimitriou A,Darzentas N,Kouvatsi A,Tsaftaris A,Anagnostopoulos A,Rosenquist R,Stamatopoulos K

    更新日期：2010-07-01 00:00:00

  • Human cord blood long-term engrafting cells are CD34+ CD38-.

    abstract：:There have been controversies about CD34 and CD38 expression by human cord blood (CB) stem cells. Using the newborn NOD/SCID/beta2-microglobulin-null mouse assay that we recently developed, we examined the in vivo engrafting capability of human CB cells. Almost all of the 4-5 months engrafting cells were found in CD34...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402878

    authors： Ishikawa F,Livingston AG,Minamiguchi H,Wingard JR,Ogawa M

    更新日期：2003-05-01 00:00:00

  • BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.

    abstract：:Synergistic molecular vulnerabilities enhancing hypomethylating agents in myeloid malignancies have remained elusive. RNA-interference drug modifier screens identified antiapoptotic BCL-2 family members as potent 5-Azacytidine-sensitizing targets. In further dissecting BCL-XL, BCL-2 and MCL-1 contribution to 5-Azacyti...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2014.44

    authors： Bogenberger JM,Kornblau SM,Pierceall WE,Lena R,Chow D,Shi CX,Mantei J,Ahmann G,Gonzales IM,Choudhary A,Valdez R,Camoriano J,Fauble V,Tiedemann RE,Qiu YH,Coombes KR,Cardone M,Braggio E,Yin H,Azorsa DO,Mesa RA,Ste

    更新日期：2014-08-01 00:00:00